DOCSLIB.ORG

Presentation Title

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Presentation Title The Aggrecanase OA Research Transitioning into Clinical Data Where Are We and What May We Expect? Ellen van der Aar, PhD Project Leader Early Development Galapagos NV, Mechelen, Belgium Clinical Trial Symposium, OARSI meeting, Toronto, Canada 1 May 2019 Disclosure information I am a Galapagos employee AND My presentation does not include discussion of off-label or investigational use Ellen van der Aar, PhD Project Leader Early Development Galapagos NV, Mechelen, Belgium 2 Cartilage breakdown • Aggrecan provides cartilage with compressibility and elasticity • Loss of aggrecan from the cartilage results in serious impairment of joint function • Cleavage of aggrecan in the interglobular domain via Matrix metalloproteinases (MMPs) at the Asn341–Phe342 bond Metalloproteinases called 'aggrecanases' at the Glu373–Ala374 bond ADAMTS4 and ADAMTS5 Fosang, A. J. Bioch. et Biophys. Acta 2011, 1812, 1616 3 ADAMTS-5 A promising therapeutic target in OA • ADAMTS-5 plays a key role in aggrecan degradation in OA • Strong literature evidence for ADAMTS-5: validated in human OA cartilage explants1 adamts-5-/- mice were protected from cartilage degradation and mechanical allodynia in DMM model2 mice treated with ADAMTS-5 mAb had attenuated joint damage and were protected from mechanical allodynia3 ARGS levels increased in human knee synovial fluid in OA4 Source: ¹ Song, 2007; ² Glasson, 2005 & Malfait, 2010; ³ Miller, 2016; 4 Larsson, 2009 4 Anti-catabolic DMOAD development with GSK2394002 • MMP inhibitors: unacceptable adverse events, lack of bioavailability, lack of efficacy • Aggrecanase inhibitors AGG-523 (Pfizer): ADAMTS-4/5 small molecule inhibitor with poor pharmacokinetics, terminated after Ph1 GSK2394002 (GSK): ADAMTS-5 monoclonal antibody, terminated in preclinical phase (increase in arterial pressure and elevated ST segment in safety pharmacology study in cynomolgus monkey (potentially irreversible)) Larkin et al, OARSI 2014 5 GLPG1972 in vitro profiling High potency and selectivity Target Selectivity (fold) ADAMTS-5 - ADAMTS-4 > 5 ADAMTS-1 >150 GLPG1972 ADAMTS-13 IC50 range (nM) > 5,000 h-ADAMTS-5 potency <25 ADAM17 (TACE) > 1,000 r-ADAMTS-5 potency <25 MMP-1 > 1,500 h-ADAMTS-5 (Aggrecan-ELISA) <70 MMP-2 > 50 MMP-7 > 1,500 MMP-9 > 500 MMP-13 > 1,000 MMP-14 > 150 Amantini et al, OARSI 2017 6 GLPG1972 in vitro profiling Human cartilage explants: IC50< 1 µM 700 GLPG1972 0.1 µM Human articular cartilage from IL-1b trigger GLPG1972 1 µM OA patient 600 GLPG1972 10 µM ) 500 mL / 12-19 days triggering with 400 ng *** IL1β +/- GLPG1972 *** 300 AGNx1 AGNx1 ( 200 Quantification of AGNx1 in the *** supernatant 100 *** *** *** *** 0 DayDay12 12 DayDay19 19 GLPG1972 features high potency on ADAMTS-5 resulting in strong anti-catabolic activity Amantini et al, OARSI 2017 7 In vivo mouse DMM Reduction in structural cartilage damage ArticularCartilage Cartilage Cumulative PG Cumulative Structure Score Score 2030 15 - 23% - 21% ¤¤ 20 - 33% 10 Score 10 5 00 Scoring system modified from Shu et al., Arthritis Rheum. 2016 vehiclevehicle G504572 30mg/kgG504572 bid 60mg/kg bid G504572 120mg/kg bid GLPG1972 30mg/kgGLPG1972 bid 60mg/kg bid GLPG1972 120mg/kg bid Amantini et al, OARSI 2017 8 In vivo rat MNX Reduction in OARSI score -6% -24% -23% *** ** OARSI SCORE OARSI Vehicle GLPG1972 GLPG1972 GLPG1972 10 mg/kg 25 mg/kg 50 mg/kg BID BID BID Data expressed as median±IQR Statistics using a stratified Kruskal-Wallis test & Dunnett multiple comparisons post hoc test ***p<0.001; **p<0.01 vs MNX-vehicle Amantini et al, OARSI 2018 9 Conclusions pharmacology GLPG1972 • Potent and selective chondroprotective ADAMTS-5 inhibitor • Orally bioavailable • Significant DMOAD effects in the mouse DMM and rat MNX models: acting on both cartilage and bone pathology (data not shown) • Robust preclinical pharmacology package with good drugability characteristics GLPG1972 was progressed to First-in-Human studies 10 Reduction of blood ARGS GLPG1972 Phase 1 study in healthy subjects (CL-101) -20 -10 0 10 placebo 20 300mg 30 600mg 40 1050mg 50 ARGS % reduction vs vs ARGS baseline % reduction ARGS % reduction vs baseline vs reduction % ARGS 60 blood 70 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Daysday post-dosing • Daily administration for 14 days was well-tolerated in healthy subjects, half life ~10h • Progressive reduction of ARGS over time until last dose at Day 14, with no significant differences between the dose levels • Maximal reduction was about 60%, with no plateau being reached Van der Aar et al, ACR 2017 11 Reduction of blood ARGS GLPG1972 Phase 1b study in OA patients (CL-104) ARGS % reduction vs vs ARGS baseline % reduction blood day • Well-tolerated in OA patients, similar PK as in healthy subjects • Dose-dependent reduction of ARGS, reaching a plateau from Day 15 onwards • After stop of treatment, ARGS return to baseline reversible effect Deckx et al, EULAR 2018 12 GLPG1972 Ready for Phase 2 1. GLPG1972 is generally safe and well-tolerated in healthy subjects and in OA patients 2. GLPG1972 shows effective target engagement by consistently reducing blood ARGS-aggrecan levels in healthy subjects and in OA patients 3. There is sufficient confidence of potential efficacy to start Ph2 development 13 Phase 2: stratification for ARGS or not? • Comparison of serum ARGS levels in OA patients and healthy subjects Literature Inhouse data: CL-101/CL-104 Baseline serum ARGS (mean ± sem) 0.250 ) 0.200 nM 0.150 ARGS ARGS ( 0.100 serum 0.050 Baseline Baseline 0.000 CL-104 CL-101 OA patients Healthy subjects Germaschewski, O&C 2014 14 Phase 2: stratification for ARGS or not? • No correlation observed between % reduction of ARGS at D15, 22 or 29 and absolute ARGS levels at baseline (in study CL-104) ARGS baseline (nM) • No ARGS stratification applied in Phase 2 study • Determination of serum ARGS is planned in Phase 2 study for retrospective analyses 15 ROCCELLA Phase 2 trial (NCT03595618) 52 weeks ‘1972 dose A ‘1972 dose B screening follow-up Topline Part 1 expected‘1972 dose Q3 C ‘18 placebo • 852 patients with knee osteoarthritis, recruited globally • 3 dose levels of GLPG1972 + placebo • 213 subjects/cohort Recruitment complete in 4Q19, topline results 1Q21 16 Key inclusion criteria ROCCELLA • Male or female of NCBP (40-75y) • Diagnosed for knee OA based on clinical and radiological criteria of the American College of Rheumatology • History of knee pain for at least 6 months and on the majority of days (>50%) during the preceding month • Symptom severity defined by a pain ≥ 40 mm and ≤ 90 mm on VAS (100 mm) • Documented need for symptomatic as needed-treatment for OA in the target knee with systemic non-steroidal anti-inflammatory drugs (NSAIDs) and/or other analgesics 17 Key objectives ROCCELLA • Primary Efficacy Objective: to demonstrate for at least one dose, a significant reduction of cartilage loss in the medial compartment of the target knee, compared to placebo (qMRI) • Key Secondary objectives: Safety and tolerability Efficacy based on structural changes (qMRI, X-ray) Efficacy based on clinical changes (WOMAC pain, stiffness and function, pain VAS) PK • Exploratory objectives: PD (ARGS) and other soluble biomarkers 18 GLPG1972 obtained fast track from FDA Fast Track Program • serious or life-threatening diseases or conditions and that demonstrate the potential to address unmet medical needs • get important new drugs to patients earlier 19 GLPG1972 Summary Mouse explants Anti-catabolic activity Human explants DMOAD Clinical Rat MNX activity Mouse DMM biomarker dataset Structural Cartilage Damage Cartilage Structural serum serum ARGS baseline %reduction vs day 20 GLPG1972 Next steps • Topline results ROCCELLA Ph2 trial in 1Q21 If negative: no need to think “what if…” It is really negative . Post-hoc analyses could help identifying subgroup(s) with treatment effects If positive: good chance for positive Ph3 study . Post-hoc analyses could help identifying subgroup(s) with stronger treatment effects • Considerations towards Ph3 Duration treatment (1-2 year); extension Structural endpoints (X-ray and/or MRI) Clinical endpoints, PROs Subgroups and potential stratification Need to meet structural AND clinical endpoints for registration? 21 Acknowledgement Department of Clinical Sciences Staffan Larsson, André Struglics, Stefan Lohmander 22.
Load more

Recommended publications
  • And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment
    International Journal of Molecular Sciences Review Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment Stephan Niland and Johannes A. Eble * Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected] Abstract: The tumor microenvironment (TME) has become the focus of interest in cancer research and treatment. It includes the extracellular matrix (ECM) and ECM-modifying enzymes that are secreted by cancer and neighboring cells. The ECM serves both to anchor the tumor cells embedded in it and as a means of communication between the various cellular and non-cellular components of the TME. The cells of the TME modify their surrounding cancer-characteristic ECM. This in turn provides feedback to them via cellular receptors, thereby regulating, together with cytokines and exosomes, differentiation processes as well as tumor progression and spread. Matrix remodeling is accomplished by altering the repertoire of ECM components and by biophysical changes in stiffness and tension caused by ECM-crosslinking and ECM-degrading enzymes, in particular matrix metalloproteinases (MMPs). These can degrade ECM barriers or, by partial proteolysis, release soluble ECM fragments called matrikines, which influence cells inside and outside the TME. This review examines the changes in the ECM of the TME and the interaction between cells and the ECM, with a particular focus on MMPs. Keywords: tumor microenvironment; extracellular matrix; integrins; matrix metalloproteinases; matrikines Citation: Niland, S.; Eble, J.A. Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix 1. Introduction Interactions in the Tumor Microenvironment.
    [Show full text]
  • Human ADAM12 Quantikine ELISA
    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Quantikine® ELISA
    Quantikine® ELISA Human ADAMTS13 Immunoassay Catalog Number DADT130 For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS13) concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................4 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Association of ADAM12 Gene Polymorphisms with Knee Osteoarthritis Susceptibility
    www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 Association of ADAM12 gene polymorphisms with knee osteoarthritis susceptibility SUPPLEMENTARY MATERIALS REFERENCES candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum. 2004;50:2497-2507. 1. Poonpet T, Tammachote R, Tammachote N, Kanitnate S, 11. Kerna I, Kisand K, Laitinen P, Tamm A, Tamm A. Honsawek S. Association between ADAM12 polymorphism Association of metallopeptidase domain 12 (ADAM12) and knee osteoarthritis in Thai population. Knee. gene polymorphisms and ADAM12 protein with the 2016;23:357-361. development of knee osteoarthritis. Osteoarthritis Cartilage. 2. Wang L, Guo L, Tian F, Hao R, Yang T. Analysis of single 2010;18. nucleotide polymorphisms within ADAM12 and risk of 12. Stark K, Straub RH, Blažičková S, Hengstenberg C, knee osteoarthritis in a Chinese Han population. Biomed Rovenský J. Genetics in neuroendocrine immunology: Res Int. 2015;2015:518643. implications for rheumatoid arthritis and osteoarthritis. Ann 3. Lou S, Zhao Z, Qian J, Zhao K, Wang R. Association N Y Acad Sci. 2010;1193. of single nucleotide polymorphisms in ADAM12 gene 13. Limer KL, Tosh K, Bujac SR, McConnell R, Doherty S, with susceptibility to kneeosteoarthritis: a case-control Nyberg F, Zhang W, Doherty M, Muir KR, Maciewicz study in a Chinese Han population. Int J Clin Exp Pathol. RA. Attempt to replicate published genetic associations 2014;7:5154-5159. in a large, well-defined osteoarthritis case-control 4. Kerna I, Kisand K, Tamm AE, Kumm J, Tamm AO. population (the GOAL study). Osteoarthritis Cartilage. Two single-nucleotide polymorphisms in ADAM12 2009;17:782-789. gene are associated with early and late radiographic 14.
    [Show full text]
  • ADAMTS13 and 15 Are Not Regulated by the Full Length and N‑Terminal Domain Forms of TIMP‑1, ‑2, ‑3 and ‑4
    BIOMEDICAL REPORTS 4: 73-78, 2016 ADAMTS13 and 15 are not regulated by the full length and N‑terminal domain forms of TIMP‑1, ‑2, ‑3 and ‑4 CENQI GUO, ANASTASIA TSIGKOU and MENG HUEE LEE Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China Received June 29, 2015; Accepted July 15, 2015 DOI: 10.3892/br.2015.535 Abstract. A disintegrin and metalloproteinase with thom- proteolysis activities associated with arthritis, morphogenesis, bospondin motifs (ADAMTS) 13 and 15 are secreted zinc angiogenesis and even ovulation [as reviewed previously (1,2)]. proteinases involved in the turnover of von Willebrand factor Also known as the VWF-cleaving protease, ADAMTS13 and cancer suppression. In the present study, ADAMTS13 is noted for its ability in cleaving and reducing the size of the and 15 were subjected to inhibition studies with the full-length ultra-large (UL) form of the VWF. Reduction in ADAMTS13 and N-terminal domain forms of tissue inhibitor of metallo- activity from either hereditary or acquired deficiency causes proteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit accumulation of UL-VWF multimers, platelet aggregation and the ADAMTS proteinases in the full-length or N-terminal arterial thrombosis that leads to fatal thrombotic thrombocy- domain form. While ADAMTS13 is also not sensitive to the topenic purpura [as reviewed previously (1,3)]. By contrast, hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 ADAMTS15 is a potential tumor suppressor. Only a limited app can be effectively inhibited by batimastat (Ki 299 nM). In number of in-depth investigations have been carried out on the conclusion, the present results indicate that TIMPs are not the enzyme; however, expression and profiling studies have shown regulators of these two ADAMTS proteinases.
    [Show full text]
  • ADAMTS Proteases in Vascular Biology
    Review MATBIO-1141; No. of pages: 8; 4C: 3, 6 ADAMTS proteases in vascular biology Juan Carlos Rodríguez-Manzaneque 1, Rubén Fernández-Rodríguez 1, Francisco Javier Rodríguez-Baena 1 and M. Luisa Iruela-Arispe 2 1 - GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain 2 - Department of Molecular, Cell, and Developmental Biology, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA Correspondence to Juan Carlos Rodríguez-Manzaneque and M. Luisa Iruela-Arispe: J.C Rodríguez-Manzaneque is to be contacted at: GENYO, 15 PTS Granada - Avda. de la Ilustración 114, Granada 18016, Spain; M.L. Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, UCLA, 615 Charles Young Drive East, Los Angeles, CA 90095, USA. [email protected]; [email protected] http://dx.doi.org/10.1016/j.matbio.2015.02.004 Edited by W.C. Parks and S. Apte Abstract ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15 years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise.
    [Show full text]
  • ADAMTS5 Assay, Human
    K-ASSAY KAMIKAMIYAYA BIOMEDICAL COMPANY KAMIYA BIOMEDICAL COMPANY ADAMTS5 Assay For the quantitative determination of human ADAMTS5 mRNA in whole blood, plasma, urine and transplantation tissue Cat. No. KT-697 For research use only, not for use in diagnostic procedures. 1 Revised 9815444 K-ASSAY KAMIKAMIYAYA BIOMEDICAL COMPANY PRODUCT INFORMATION ADAMTS5 Assay Cat. No. KT-697 PRODUCT The K-ASSAY ADAMTS5 Assay is a real time PCR assay for the quantitative determination of human ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) mRNA in whole blood, plasma, urine and transplantation tissue. For research use only. Not for use in diagnostic procedures. INTRODUCTION Aggrecan is the major proteoglycan in cartilage, and is degraded by ADAMTS5 in arthritic cartilage. Studies in models of cultured bovine and porcine chondrocytes and cartilage explants have reported that ADAMTS5 is not induced by stimulation with IL-1 and TNF α. It has also been shown that ADAMTS5 expression in human synoviocytes is not inhibited by the anti-TNF biologics. PRINCIPLE ADAMTS5 TEST Kit contains specific primers, probes and calibrator DNA for the detection and quantification of human ADAMTS5 mRNA in samples. The test is based on real-time PCR that, in addition to specific forward and reverse oligonucleotide primers, utilizes MGB (minor groove binder) probe to generate a fluorescent signal when specific cDNA is present in samples. Samples, such as whole blood, plasma, urine, and transplantation tissue can be used. COMPONENTS Master Mix: 1 vial, 900 µL ADAMTS5 MGB Probe: 1 vial, 45 µL β-actin MGB Probe: 1 vial, 45 µL ADAMTS5 calibrator DNA: 1 vial, 50 µL β-actin calibrator DNA: 1 vial, 50 µL Each kit contains enough reagents to perform 21 tests.
    [Show full text]
  • Podocin Inactivation in Mature Kidneys Causes Focal Segmental Glomerulosclerosis and Nephrotic Syndrome
    BASIC RESEARCH www.jasn.org Podocin Inactivation in Mature Kidneys Causes Focal Segmental Glomerulosclerosis and Nephrotic Syndrome Ge´raldine Mollet,*† Julien Ratelade,*† Olivia Boyer,*†‡ Andrea Onetti Muda,*§ ʈ Ludivine Morisset,*† Tiphaine Aguirre Lavin,*† David Kitzis,*† Margaret J. Dallman, ʈ Laurence Bugeon, Norbert Hubner,¶ Marie-Claire Gubler,*† Corinne Antignac,*†** and Ernie L. Esquivel*† *INSERM, U574, Hoˆpital Necker-Enfants Malades, Paris, France; †Faculte´deMe´ decine Rene´ Descartes, Universite´ Paris Descartes, Paris, France; ‡Pediatric Nephrology Department and **Department of Genetics, Hoˆpital Necker- Enfants Malades, Assistance Publique-Hoˆpitaux de Paris, Paris, France; §Department of Pathology, Campus ʈ Biomedico University, Rome, Italy; Department of Biological Sciences, Imperial College London, London, England; and ¶Max-Delbruck Center for Molecular Medicine, Berlin, Germany ABSTRACT Podocin is a critical component of the glomerular slit diaphragm, and genetic mutations lead to both familial and sporadic forms of steroid-resistant nephrotic syndrome. In mice, constitutive absence of podocin leads to rapidly progressive renal disease characterized by mesangiolysis and/or mesangial sclerosis and nephrotic syndrome. Using established Cre-loxP technology, we inactivated podocin in the adult mouse kidney in a podocyte-specific manner. Progressive loss of podocin in the glomerulus recapitu- lated albuminuria, hypercholesterolemia, hypertension, and renal failure seen in nephrotic syndrome in humans. Lesions of FSGS appeared
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • ADAMTS-5: Issnthe Story 1473-2262 So Far
    AJ.European Fosang Cells et al. and Materials Vol. 15 200 8 (pages 11-26) DOI: 10.22203/eCM.v015a02 ADAMTS-5: ISSNThe story 1473-2262 so far ADAMTS-5: THE STORY SO FAR Amanda J. Fosang*, Fraser M. Rogerson, Charlotte J. East, Heather Stanton University of Melbourne Department of Paediatrics and Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia Abstract List of abbreviations The recent discovery of ADAMTS-5 as the major ADAM A disintegrin and metalloproteinase aggrecanase in mouse cartilage came as a surprise. A great ADAMTS A disintegrin and metalloproteinase with deal of research had focused on ADAMTS-4 and much thrombospondin motifs less was known about the regulation, expression and activity CS Chondroitin sulphate of ADAMTS-5. Two years on, it is still not clear whether CS-2 Second chondroitin sulphate domain ADAMTS-4 or ADAMTS-5 is the major aggrecanase in G1 First (N-terminal) globular domain of human cartilage. On the one hand there are in vitro studies aggrecan using siRNA, neutralising antibodies and immuno- G2 Second (N-terminal) globular domain of precipitation with anti-ADAMTS antibodies that suggest aggrecan a significant role for ADAMTS-4 in aggrecanolysis. On IGD Interglobular domain of aggrecan the other hand, ADAMTS-5 (but not ADAMTS-4)-deficient KS Keratan sulphate mice are protected from cartilage erosion in models of MMP Matrix metalloproteinase experimental arthritis, and recombinant human ADAMTS- TIMP Tissue inhibitor of matrix metalloproteinase 5 is substantially more active than ADAMTS-4. The activity TS Thrombospondin of both enzymes is modulated by C-terminal processing, α2M α2-Macroglobulin which occurs naturally in vivo.
    [Show full text]
  • Vitro Generated to Ex Vivo CD8 T Cells Comparative and Functional
    Downloaded from http://www.jimmunol.org/ by guest on September 24, 2021 is online at: average * The Journal of Immunology published online 27 August 2012 from submission to initial decision 4 weeks from acceptance to publication Comparative and Functional Evaluation of In Vitro Generated to Ex Vivo CD8 T Cells Dzana D. Dervovic, Maria Ciofani, Korosh Kianizad and Juan Carlos Zúñiga-Pflücker J Immunol http://www.jimmunol.org/content/early/2012/08/26/jimmun ol.1200979 Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2012/08/28/jimmunol.120097 9.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 24, 2021. Published August 27, 2012, doi:10.4049/jimmunol.1200979 The Journal of Immunology Comparative and Functional Evaluation of In Vitro Generated to Ex Vivo CD8 T Cells Dzˇana D. Dervovic´,*,† Maria Ciofani,*,†,1 Korosh Kianizad,*,† and Juan Carlos Zu´n˜iga-Pflu¨cker*,† The generation of the cytotoxic CD8 T cell response is dependent on the functional outcomes imposed by the intrathymic constraints of differentiation and self-tolerance.
    [Show full text]
  • Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma
    Published OnlineFirst March 21, 2010; DOI: 10.1158/1078-0432.CCR-09-2525 Clinical Human Cancer Biology Cancer Research Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Angela Stokes1, Juho Joutsa6,7,8,9, Risto Ala-aho6,8, Mark Pitchers1, Caroline J. Pennington1, Craig Martin2, Don J. Premachandra3, Yasunori Okada10, Juha Peltonen4, Reidar Grénman5,7, Helen A. James1, Dylan R. Edwards1, and Veli-Matti Kähäri6,7,8 Abstract Purpose: Head and neck squamous cell carcinomas (HNSCC) are characterized by high morbidity and mortality, largely due to the high invasive and metastatic potential of these tumors, high recurrence rates, and low treatment responses. Proteinases have been implicated in several aspects of tumor growth and metastasis in a broad range of tumors including HNSCC. Experimental Design: Comprehensive expression profiling of proteinases [matrix metalloproteinases (MMPs), A disintegrin and metalloproteinase (ADAMs), and ADAMs with thrombospondin motif (ADAMTSs)] and their inhibitors [tissue inhibitor of metalloproteinases (TIMPs)] was done using quanti- tative real-time reverse transcription-PCR analysis of a large cohort of tissue samples representing the tumor (n = 83), the invasive margin (n = 41), and the adjacent tissue (n = 41) from 83 HNSCC patients, along with normal tissue controls (n = 13), as well as cell lines established from tumors of 34 HNSCC patients. Results: The results show specifically elevated gene expression of several proteinases, including MMP1, MMP3, MMP10, and MMP13 within tumor tissue and peritumoral adjacent tissue. In addition, the results identify several novel HNSCC-associated proteinases, including ADAM8, ADAM9, ADAM17, ADAM28, ADAMTS1, ADAMTS8, and ADAMTS15.
    [Show full text]